(Q34551322)

3 August 2017

1 reference

title

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design (English)

1 reference

3 August 2017

0 references

1 reference

Patrick K Owiafe

4

0 references

Helen Fletcher

object named as

Helen A Fletcher

5

0 references

Adrian V. S. Hill

7

object named as

Adrian V S Hill

1 reference

3 August 2017

9

Helen McShane

1 reference

3 August 2017

Richard Adebayo Adegbola

8

object named as

Richard A Adegbola

1 reference

3 August 2017

6

Christian Lienhardt

1 reference

3 August 2017

Hannah B Ibanga

1

1 reference

3 August 2017

Roger H Brookes

2

1 reference

3 August 2017

Philip C Hill

3

1 reference

3 August 2017

publication date

1 August 2006

1 reference

Lancet Infectious Diseases

3 August 2017

published in

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

522-528

1 reference

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

BCG--different strains, different vaccines?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

BCG vaccination and nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Immunology of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

How can immunology contribute to the control of tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Correlates of protective immunity to Mycobacterium tuberculosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Advances in tuberculosis vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Tuberculosis vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Cytokines and the Koch phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Evolution and current use of the tuberculin test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guérin: recent Mycobacterium tuberculosis infection or booster effect?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Tuberculin and Anergy Testing in HIV-Seropositive and HIV-Seronegative Persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Diagnosing latent tuberculosis infection: turning glitter to gold

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

The Potential of the ESAT-6 Antigen Secreted by Virulent Mycobacteria for Specific Diagnosis of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Rapid effector function in CD8+ memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Tuberculin response two years after BCG vaccination at birth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

Undue inducement in clinical research in developing countries: is it a worry?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970552-7

7 January 2021

10.1016/S1473-3099(06)70552-7

Identifiers

DOI

1 reference

3 August 2017

1 reference